The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC).
David Goldstein
Consultant or Advisory Role - Celgene (U)
Research Funding - Celgene
Robert Hassan El-Maraghi
Consultant or Advisory Role - Celgene
Research Funding - Celgene
Pascal Hammel
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Volker Heinemann
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Other Remuneration - Celgene
Volker Kunzmann
Consultant or Advisory Role - Celgene
Javier Sastre
No relevant relationships to disclose
Werner Scheithauer
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Salvatore Siena
Consultant or Advisory Role - Amgen; Bayer; Celgene; Roche; Sanofi
Teresa Macarulla
No relevant relationships to disclose
Luis Teixeira
No relevant relationships to disclose
Giampaolo Tortora
Research Funding - Celgene
Jean Luc Van Laethem
No relevant relationships to disclose
Darryl Neil Penenberg
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Brian Lu
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Alfredo Romano
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Daniel D. Von Hoff
Consultant or Advisory Role - Celgene (U)
Honoraria - Celgene (I)
Research Funding - TGen